Alpha-2 Agonists for Glaucoma
Learn alpha-2 agonists for glaucoma, including brimonidine, apraclonidine, adverse effects and Horner syndrome testing.
Which of the following is an alpha-2 adrenergic agonist used in glaucoma therapy?
Alpha-2 Agonists in 30 Seconds
Alpha-2 agonists lower IOP by reducing aqueous production and increasing uveoscleral outflow. Brimonidine is the primary agent for chronic adjunctive therapy, while apraclonidine is reserved for short-term indications such as post-laser IOP spikes and pharmacologic testing for Horner syndrome.
Mechanism and IOP Lowering
Alpha-2 receptor agonism decreases cyclic AMP production in the nonpigmented ciliary epithelium, reducing aqueous humor secretion, while also modestly increasing uveoscleral outflow, producing roughly 20 to 25% IOP reduction. Unlike beta-blockers, alpha-2 agonists retain some nocturnal effect. Brimonidine shows neuroprotective effects in animal models, but human clinical neuroprotection remains unproven. The dual mechanism of reduced aqueous production plus increased uveoscleral outflow is a classic board teaching point.
Agents and Uses
- Brimonidine (Alphagan P): primary alpha-2 agonist for chronic adjunctive glaucoma management, dosed twice or three times daily. Contraindicated in children younger than 2 years because of profound CNS and respiratory depression risk. Exam relevance: infant CNS contraindication is the highest-yield safety point.
- Apraclonidine: less selective, reserved for short-term use (post-laser IOP spikes, perioperative). Tachyphylaxis and high rates of allergic reactions preclude chronic use. Exam relevance: tachyphylaxis and allergy explain why it is not used for chronic therapy.
- Apraclonidine 0.5% for Horner testing: reverses anisocoria and often partially reverses ptosis through denervation supersensitivity of the iris dilator. Has largely replaced cocaine as the preferred confirmation test because it is more readily available. Exam relevance: the reversal of Horner anisocoria by apraclonidine is the key positive finding.
Side Effects and Contraindications
- Ocular allergy: follicular conjunctivitis and contact dermatitis, particularly with apraclonidine and brimonidine. Allergic follicular conjunctivitis from brimonidine often develops months after starting therapy. Exam relevance: major reason for discontinuation.
- CNS depression in infants: brimonidine crosses the immature blood-brain barrier and causes apnea, somnolence and bradycardia. Absolutely contraindicated in children under 2 years. Exam relevance: most important safety contraindication.
- Systemic effects: dry mouth, fatigue, drowsiness and light-headedness from central alpha-2 effects. Exam relevance: alpha-2 agonism causes CNS depression.
- Drug interactions: additive CNS depression with sedatives, use caution or avoid with MAO inhibitors. Exam relevance: always review medication history.
- Horner physiology pearl: brimonidine causes miosis in normal eyes but causes mydriasis in Horner syndrome because denervation supersensitivity amplifies the dilator response. Exam relevance: a classic physiology distinction.
4 Facts Exams Always Ask
- Brimonidine has a dual mechanism: reduces aqueous production AND increases uveoscleral outflow via cyclic AMP reduction.
- Contraindicated in children younger than 2 years because brimonidine crosses the immature blood-brain barrier and causes CNS and respiratory depression.
- Apraclonidine is used for short-term indications (post-laser IOP spikes) and for pharmacologic confirmation of Horner syndrome through denervation supersensitivity.
- Tachyphylaxis limits long-term apraclonidine use; brimonidine is the agent for chronic adjunctive therapy.
The Classic Trap
Do not prescribe brimonidine to a neonate or young child under 2 years because profound CNS and respiratory depression can occur. For Horner syndrome testing: apraclonidine reverses the anisocoria and ptosis of Horner syndrome by stimulating the supersensitive denervated dilator muscle, while cocaine confirms Horner syndrome because the affected eye fails to dilate. Apraclonidine has largely replaced cocaine in modern practice.
Clinical Pearl
The apraclonidine test is the highest-yield board point: apraclonidine 0.5% or 1% reverses Horner anisocoria and ptosis by stimulating the denervated iris dilator through denervation supersensitivity. This has largely replaced cocaine as the preferred confirmation test. Cocaine confirms Horner by failure of dilation. Hydroxyamphetamine then localizes the lesion as preganglionic or postganglionic.
Checkpoint 1
Brimonidine is generally avoided in infants and young children primarily due to which risk?
Checkpoint 2
Why is apraclonidine primarily used for short-term IOP control (e.g., preventing post-laser IOP spikes) rather than chronic glaucoma therapy, unlike brimonidine?
A 42-year-old patient has right ptosis, right miosis and anisocoria greater in darkness. After apraclonidine 0.5% is instilled in both eyes, the right pupil dilates more than the left and the right upper lid partially elevates. What diagnosis does this pharmacologic response confirm?
After apraclonidine 0.5% is instilled in both eyes of a patient with right ptosis and right miosis, the right pupil dilates more than the left and the right lid partially elevates. What does this response confirm?
Sources & Publisher Info
Last clinically reviewed: August 9, 2026
References
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 10: Glaucoma.
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 5: Neuro-Ophthalmology.
- American Academy of Ophthalmology. EyeWiki: Glaucoma Medical Therapy.
- American Academy of Ophthalmology. EyeWiki: Horner Syndrome.
More Pharmacology topics
Ready for the real thing?
Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.
Practice Pharmacology →